Diseases, Conditions, Syndromes

Higher dose of steroid does not improve outcomes in severe COVID-19

(HealthDay)—The number of days alive without life support at day 28 did not differ among adults with COVID-19 and severe hypoxemia receiving dexamethasone 12 mg/day versus dexamethasone 6 mg/day administered intravenously ...

Surgery

Inhaled betadine leads to rare complication

A routine step in preparing for cleft palate surgery in a child led to an unusual—but not unprecedented—case of lung inflammation (pneumonitis), according to a report in the The Journal of Craniofacial Surgery.

Diseases, Conditions, Syndromes

Giving distressed lungs a safer fighting chance

A device designed at the University of Pittsburgh could help improve outcomes as a treatment for COVID-19 when used in conjunction with non-invasive or mechanical ventilation, and it recently received Emergency Use Authorization ...

Diseases, Conditions, Syndromes

A COVID-19 palliative care pandemic plan: An essential tool

Palliative care physicians have created a coronavirus disease 2019 (COVID-19) palliative care plan as an essential tool to provide care and help manage scare resources during the pandemic. The plan, which focuses on 8 critical ...

Medications

Inhaled amikacin reduces ventilatory-associated pneumonia

For critically ill patients undergoing mechanical ventilation for at least three days, a three-day course of inhaled amikacin reduces the subsequent burden of ventilatory-associated pneumonia, according to a study published ...

Diseases, Conditions, Syndromes

Infectious Diseases Society of America meeting, some highlights

The annual meeting of the Infectious Diseases Society of America was held this year from Oct. 11 to 15 in Boston and attracted participants from around the world, including scientists, physicians, and other health care professionals.

Medications

Subcutaneous mAb may benefit high-risk outpatients with COVID-19

For high-risk outpatients with mild-to-moderate COVID-19, subcutaneously administered monoclonal antibody (mAb) treatment with casirivimab and imdevimab is associated with reduced risk for 28-day hospitalization or death ...

page 25 from 34